GMP also upregulated PD-1 and CTLA-4 expression on CD8+ T cells, suggesting that CHI3L1/galectin-3 disruption could improve the efficacy of immune checkpoint inhibitors in GBM. The gene discussed is CHI3L1; the disease is glioblastoma.